These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Influence of mucosal adjuvants on antigen passage and CD4+ T cell activation during the primary response to airborne allergen. Wikstrom ME; Batanero E; Smith M; Thomas JA; von Garnier C; Holt PG; Stumbles PA J Immunol; 2006 Jul; 177(2):913-24. PubMed ID: 16818746 [TBL] [Abstract][Full Text] [Related]
5. Protective mucosal immunity in aging is associated with functional CD4+ T cells in nasopharyngeal-associated lymphoreticular tissue. Hagiwara Y; McGhee JR; Fujihashi K; Kobayashi R; Yoshino N; Kataoka K; Etani Y; Kweon MN; Tamura S; Kurata T; Takeda Y; Kiyono H; Fujihashi K J Immunol; 2003 Feb; 170(4):1754-62. PubMed ID: 12574339 [TBL] [Abstract][Full Text] [Related]
6. The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia. Kataoka K; Fujihashi K; Oma K; Fukuyama Y; Hollingshead SK; Sekine S; Kawabata S; Ito HO; Briles DE; Oishi K Infect Immun; 2011 Jul; 79(7):2819-28. PubMed ID: 21536790 [TBL] [Abstract][Full Text] [Related]
7. Lymphotactin acts as an innate mucosal adjuvant. Lillard JW; Boyaka PN; Hedrick JA; Zlotnik A; McGhee JR J Immunol; 1999 Feb; 162(4):1959-65. PubMed ID: 9973465 [TBL] [Abstract][Full Text] [Related]
8. A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity. Fukuiwa T; Sekine S; Kobayashi R; Suzuki H; Kataoka K; Gilbert RS; Kurono Y; Boyaka PN; Krieg AM; McGhee JR; Fujihashi K Vaccine; 2008 Sep; 26(37):4849-59. PubMed ID: 18625280 [TBL] [Abstract][Full Text] [Related]
17. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. Boyaka PN; Tafaro A; Fischer R; Leppla SH; Fujihashi K; McGhee JR J Immunol; 2003 Jun; 170(11):5636-43. PubMed ID: 12759444 [TBL] [Abstract][Full Text] [Related]
18. Non-toxic Stx derivatives from Escherichia coli possess adjuvant activity for mucosal immunity. Ohmura-Hoshino M; Yamamoto M; Yuki Y; Takeda Y; Kiyono H Vaccine; 2004 Sep; 22(27-28):3751-61. PubMed ID: 15315856 [TBL] [Abstract][Full Text] [Related]
19. CD11c(high )dendritic cells are essential for activation of CD4+ T cells and generation of specific antibodies following mucosal immunization. Fahlén-Yrlid L; Gustafsson T; Westlund J; Holmberg A; Strömbeck A; Blomquist M; MacPherson GG; Holmgren J; Yrlid U J Immunol; 2009 Oct; 183(8):5032-41. PubMed ID: 19786541 [TBL] [Abstract][Full Text] [Related]